GLP-1 Drugs Enter the Addiction Medicine Arena
The blockbuster weight loss drug semaglutide — known commercially as Ozempic and Wegovy — may have a powerful new application: treating alcohol addiction. Results from a randomized, double-blind, placebo-controlled trial published this week in JAMA Psychiatry show that weekly semaglutide injections significantly reduced both alcohol consumption and cravings in adults diagnosed with alcohol use disorder (AUD).
The trial, conducted at the University of North Carolina at Chapel Hill, represents the most rigorous evidence to date supporting anecdotal reports from patients and clinicians that GLP-1 receptor agonists seem to diminish the desire to drink alcohol.
Study Design and Key Results
The 26-week trial enrolled 308 adults with moderate to severe alcohol use disorder who were not actively seeking weight loss treatment. Participants were randomly assigned to receive either weekly subcutaneous semaglutide (titrated to 2.4 mg) or matching placebo, alongside standard behavioral counseling.
The results were striking:
- Heavy drinking days (defined as 4+ drinks for women, 5+ for men) decreased by 40.2 percent in the semaglutide group versus 18.7 percent in the placebo group
- Total weekly alcohol consumption dropped by an average of 52 percent among semaglutide recipients
- Alcohol craving scores on the Penn Alcohol Craving Scale fell by 35 percent more in the treatment group
- Complete abstinence was achieved by 22 percent of semaglutide recipients versus 8 percent on placebo
"These are among the most impressive results we've seen for any pharmacological intervention for alcohol use disorder. The effect sizes rival or exceed those of currently approved medications like naltrexone and acamprosate," said Dr. Christian Hendershot, the study's lead author and associate professor of psychiatry at UNC.
How Semaglutide May Affect Alcohol Cravings
GLP-1 receptor agonists were originally developed to treat type 2 diabetes by mimicking a gut hormone that stimulates insulin production. Their weight loss effects stem from actions in the brain, where GLP-1 receptors are concentrated in areas that regulate appetite, reward, and motivation — notably the hypothalamus and the mesolimbic dopamine system.
It is this overlap with the brain's reward circuitry that researchers believe explains semaglutide's effects on alcohol consumption. Alcohol activates dopamine release in the same neural pathways that drive food-seeking behavior. By modulating these circuits, semaglutide appears to reduce the reinforcing effects of alcohol — essentially making drinking less pleasurable and less compulsive.
Preclinical studies in rodents had already demonstrated this mechanism. Rats given GLP-1 agonists consistently chose water over alcohol and showed reduced dopamine release in the nucleus accumbens when exposed to alcohol. The UNC trial confirms that these findings translate to humans.
Implications for Addiction Treatment
Alcohol use disorder affects an estimated 29 million Americans, yet fewer than 10 percent receive any treatment. Current FDA-approved medications — naltrexone, acamprosate, and disulfiram — have modest effectiveness and are vastly underutilized, prescribed to fewer than 2 percent of AUD patients.
If semaglutide receives FDA approval for alcohol addiction, it could significantly expand the treatment landscape. The drug's once-weekly dosing and familiar brand recognition may help reduce the stigma that prevents many people from seeking pharmacological help for drinking problems.
However, challenges remain. Semaglutide's current cost — approximately $1,300 per month without insurance — would be prohibitive for many AUD patients, who disproportionately face economic hardship. Novo Nordisk, the drug's manufacturer, has not commented on pricing for potential addiction indications.
What Comes Next
The UNC team is planning a larger Phase 3 trial with 1,500 participants, expected to begin enrollment in late 2026. Researchers will also investigate whether oral semaglutide formulations are as effective as injections for AUD, which could further improve accessibility.
Other GLP-1 drugs, including tirzepatide, are also being studied for addiction applications, with early-stage trials examining effects on nicotine dependence, opioid cravings, and compulsive gambling.
For now, physicians caution that semaglutide should not be used off-label for alcohol addiction outside of clinical trials. Patients struggling with AUD are encouraged to speak with their healthcare providers about currently approved treatment options.
